2.0 52e5cdba-16e0-4764-ac0f-72e4256777b5 *AOS_Prostate_LR SBRT 40Gy 5fx v1 Pelvis Prostate *AOS_Prostate LR SBRT 40Gy 5fx AOS sample template - to be copied, reviewed, modified as deemed appropriate, and approved by site physicist Summary: Low Risk Prostate SBRT 5 fx to 40 Gy. Prostate to 40 Gy, PTV to 36.25 Gy. No nodal targets. References: "Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints", Kaplan et. al, IJROBP 2018; RTOG 0938; ADAPT Marketplace Prostate SBRT Version 1.4 Created: 7/8/2024 Last updated: 4/7/2025 (PHH) - Adjusted OAR P levels ********************************************************************* Rx: ."Total Prescribed Dose: patients will receive 5 fractions of radiation; each fraction size will be 7.25 Gy. The total dose will be 36.25 Gy. The 5 treatments will be scheduled to be delivered twice a week over 15-17 days. Dose Coverage: For both arms, the isodose line used for the prescription dose should cover a minimum of 95% of the PTV. The minimum dose within the PTV to a point that is 0.03 cc in size must be ≥95% of the prescribed dose. For IMRT and proton treatments, the maximum dose within the PTV is 7% above the prescribed dose for a point that is 0.03 cc in size." - RTOG 0938 CTV: "The clinical target volume (CTV) will be the same as the GTV and will consist of the prostate without the seminal vesicles as defined by non-contrast axial CT scan." - RTOG 0938 Margins: "The planning target volume (PTV) will be defined as the CTV plus a 3 mm margin posteriorly and 5 mm in all other dimensions. To meet dose constraints, if necessary, the ant margin can be reduced to 3 mm." - RTOG 0938 OAR Contouring: "The normal tissue volume to be contoured will include bladder, rectum, bilateral femora (to the level of ischial tuberosity), seminal vesicles, penile bulb, skin, and urethra." - RTOG 0938 Structures have been named according to TG 263. 14544 FMA 3.2 Rectum 4280929481 Rectum 15900 FMA 3.2 Urinary bladder 4288990249 Bladder 19614 FMA 3.2 Penile bulb 4294937740 PenileBulb 19667 FMA 3.2 Urethra 4278255615 Urethra 7199 FMA 3.2 Bowel 4291439052 Bowel 45643 FMA 3.2 Genitals 4278222912 Genitals 24474 FMA 3.2 Femur whole right 4294934592 Femur_R 24475 FMA 3.2 Femur whole left 4278190335 Femur_L 19386 FMA 3.2 Seminal vesicle 4291570075 Seminal vesicle 9600 FMA 3.2 Prostate 4286458316 Prostate R-429EC SRT Planning target volume 4294901760 PTV Target2 R-429EB SRT Clinical target volume 5 3 5 5 3 5 ]]> R-429EB SRT Clinical target volume 4280918220 CTV OAR10 9600 FMA 3.2 Prostate ]]> NormalTissue 99VMS_STRUCTCODE 1.0 Unidentified structure 4278223103 NVB PRV 99VMS_STRUCTCODE 1.0 Planning organ-at-risk volume 4278222976 Urethra_PRV_02 OAR4 19667 FMA 3.2 Urethra 2 ]]> NormalTissue 99VMS_STRUCTCODE 1.0 Unidentified structure 4278190240 NVB_PRV_02 ControlRegion1 NormalTissue 99VMS_STRUCTCODE 1.0 Unidentified structure 2 Target2 R-429EB SRT Clinical target volume ]]> NormalTissue 99VMS_STRUCTCODE 1.0 Unidentified structure 4289604044 Skin_PTV_03 Body BODY 99VMS_STRUCTCODE 1.0 Body plus other external items 3 0 ]]> Target1 7.25 VolumeDose ShouldBeMoreOrEqual 95 Relative 36.25 Absolute VolumeDose ShouldBeMoreOrEqual 90 Relative 36.25 Absolute 2 2 DoseVolume ShouldBeMoreOrEqual 99 Relative 35 Absolute DoseVolume ShouldBeMoreOrEqual 99 Relative 30 Absolute 2 4 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 42.8 Absolute 3 7 Target2 8 VolumeDose ShouldBeMoreOrEqual 95 Relative 40 Absolute VolumeDose ShouldBeMoreOrEqual 90 Relative 40 Absolute 1 1 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 42.8 Absolute DoseVolume ShouldBeLessOrEqual 0.03 Absolute 46 Absolute 3 1 OAR1 VolumeDose ShouldBeLessOrEqual 1 Absolute 36 Absolute VolumeDose ShouldBeLessOrEqual 2 Absolute 36 Absolute 2 3 OAR1 DoseVolume ShouldBeLessOrEqual 90 Relative 32.6 Absolute 3 6 OAR1 DoseVolume ShouldBeLessOrEqual 80 Relative 29 Absolute 3 5 OAR1 DoseVolume ShouldBeLessOrEqual 50 Relative 18 Absolute 3 2 OAR1 MeanDose OAR2 DoseVolume ShouldBeLessOrEqual 1 Absolute 38 Absolute DoseVolume ShouldBeLessOrEqual 1 Absolute 40 Absolute 2 10 OAR2 VolumeDose ShouldBeLessOrEqual 5 Absolute 37 Absolute VolumeDose ShouldBeLessOrEqual 10 Absolute 37 Absolute 2 5 OAR2 DoseVolume ShouldBeLessOrEqual 90 Relative 32.63 Absolute DoseVolume ShouldBeLessOrEqual 90 Relative 34 Absolute 3 4 OAR2 DoseVolume ShouldBeLessOrEqual 50 Relative 18.13 Absolute DoseVolume ShouldBeLessOrEqual 50 Relative 20 Absolute 3 3 OAR2 MeanDose OAR3 VolumeDose ShouldBeLessOrEqual 50 Relative 29.5 Absolute 2 7 OAR3 VolumeDose ShouldBeLessOrEqual 3 Absolute 20 Absolute VolumeDose ShouldBeLessOrEqual 5 Absolute 20 Absolute 3 8 OAR3 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 36.25 Absolute 2 8 OAR4 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 38.8 Absolute DoseVolume ShouldBeLessOrEqual 0.03 Absolute 40 Absolute 2 9 OAR4 VolumeDose ShouldBeLessOrEqual 20 Relative 47 Absolute VolumeDose ShouldBeLessOrEqual 25 Relative 47 Absolute 1 2 OAR5 VolumeDose ShouldBeLessOrEqual 1 Absolute 30 Absolute VolumeDose ShouldBeLessOrEqual 5 Absolute 30 Absolute 2 11 OAR5 MeanDose ControlRegion1 VolumeDose ShouldBeLessOrEqual 50 Relative 38 Absolute 2 12 ControlRegion1 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 40 Absolute 3 9 ControlRegion2 MaximumDose ShouldBeLessOrEqual 0 Absolute 40.5 Absolute MaximumDose ShouldBeLessOrEqual 0 Absolute 42 Absolute 1 3 ControlRegion2 DoseVolume ShouldBeLessOrEqual 50 Relative 40 Absolute DoseVolume ShouldBeLessOrEqual 50 Relative 41 Absolute 2 1 ControlRegion3 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 41 Absolute 2 6 ControlRegion3 MeanDose ShouldBeLessOrEqual 36 Absolute MeanDose ShouldBeLessOrEqual 38 Absolute 3 10 OAR6 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 2 Absolute 4 1 OAR7 VolumeDose ShouldBeLessOrEqual 10 Absolute 20 Absolute 3 11 OAR8 VolumeDose ShouldBeLessOrEqual 10 Absolute 20 Absolute 3 12 ControlRegion4 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 10 Absolute DoseVolume ShouldBeLessOrEqual 0.03 Absolute 30 Absolute 4 2 NoNormalization 1 None 1 None 1 None 1 None 1 None